Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis Abstract #25

Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Aim(s): To define factors that predict response to radio-embolization in patients with NET liver metastases.
Materials and methods: All patients with NET liver metastasis that were radio-embolized with TheraSphere ® (glass microspheres) from January 2006 until March 2009 were reviewed. Patients were followed with triphasic CT-scans prior to, and serially after, treatment starting at four weeks. Response was determined by change in percentage of necrosis (ΔN%) after the first radio-embolization. A univariate and multivariate analysis was carried out with the following variables: age, sex, size (4 cm), liver involvement (66%), WHO classification, presence of extra-hepatic metastasis, octereotide treatment, and previous operative (surgery and RFA) and non-operative treatments (chemo-embolization and bland-embolization).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result